---
title: "Cogent Biosciences | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285203351.md"
datetime: "2026-05-05T12:10:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285203351.md)
  - [en](https://longbridge.com/en/news/285203351.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285203351.md)
---

# Cogent Biosciences | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EBIT: As of FY2026 Q1, the actual value is USD -110 M.

### Financial Performance for Q1 2026

#### Net Loss

Cogent Biosciences, Inc. reported a net loss of - $97.4 million for the first quarter of 2026, compared to a net loss of - $72.0 million for the first quarter of 2025. The net loss for the three months ended March 31, 2026, was - $97,352 thousand, compared to - $71,986 thousand for the same period in 2025.

#### Operating Expenses

Total operating expenses increased to $103,607 thousand for the first quarter of 2026 from $74,933 thousand for the first quarter of 2025.

-   **Research and Development (R&D) Expenses**: R&D expenses were $75.4 million for Q1 2026, an increase from $63.0 million for Q1 2025. This increase was primarily due to advancing early-stage, preclinical, and discovery programs into Phase 1 clinical trials and IND-enabling studies, including one-time costs from winding down the FGFR clinical program. R&D expenses included non-cash stock compensation of $8.9 million for Q1 2026, up from $5.3 million for Q1 2025. In thousands, R&D expenses were $75,365 for Q1 2026 and $63,029 for Q1 2025.
-   **General and Administrative (G&A) Expenses**: G&A expenses rose to $28.2 million for Q1 2026 from $11.9 million for Q1 2025. This increase was mainly driven by organizational growth and activities related to the anticipated commercial launch of bezuclastinib. G&A expenses included non-cash stock compensation of $8.0 million for Q1 2026, compared to $4.8 million for Q1 2025. In thousands, G&A expenses were $28,242 for Q1 2026 and $11,904 for Q1 2025.

#### Other Income (Expense)

-   **Interest Income**: Interest income was $7,608 thousand for Q1 2026, up from $2,952 thousand for Q1 2025.
-   **Interest Expense**: Interest expense was - $1,213 thousand for Q1 2026, compared to $0 for Q1 2025.
-   **Other Income (Expense), Net**: Other income (expense), net, was - $140 thousand for Q1 2026, compared to - $5 thousand for Q1 2025.
-   **Total Other Income, Net**: Total other income, net, was $6,255 thousand for Q1 2026, compared to $2,947 thousand for Q1 2025.

### Balance Sheet Data (as of March 31, 2026)

-   **Cash, Cash Equivalents and Marketable Securities**: $866.4 million, which includes net proceeds of $45.7 million from an at-the-market (ATM) stock offering and $18.0 million in non-recurring payments. In thousands, this figure was $866,378 as of March 31, 2026, a decrease from $900,765 as of December 31, 2025.
-   **Working Capital**: $819,822 thousand as of March 31, 2026, down from $846,402 thousand as of December 31, 2025.
-   **Total Assets**: $903,006 thousand as of March 31, 2026, compared to $937,607 thousand as of December 31, 2025.
-   **Total Liabilities**: $295,313 thousand as of March 31, 2026, compared to $301,236 thousand as of December 31, 2025.
-   **Total Stockholders’ Equity**: $607,693 thousand as of March 31, 2026, compared to $636,371 thousand as of December 31, 2025.

### Outlook

Cogent Biosciences, Inc. is planning for dual launches of bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST) and expects to submit a third New Drug Application (NDA) for bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) in the first half of 2026, with potential launches in the second half of 2026, pending FDA approval. The company anticipates its existing cash, cash equivalents, and marketable securities of $866.4 million will be sufficient to fund operations, including the commercialization of bezuclastinib in SM and GIST, into 2028.

### Related Stocks

- [COGT.US](https://longbridge.com/en/quote/COGT.US.md)

## Related News & Research

- [J.P. Morgan Sticks to Its Buy Rating for Cogent Biosciences (COGT)](https://longbridge.com/en/news/279124539.md)
- [Cogent Biosciences Stock Falls 6% After Submission Of New Drug Application For Bezuclastinib](https://longbridge.com/en/news/281388189.md)
- [Cogent Submits NDA For Bezuclastinib In GIS Tumours After Non-AdvSM; Eyes NDA For AdvSM In H1,2026](https://longbridge.com/en/news/281483548.md)
- [LifeSci Capital Sticks to Their Buy Rating for Cogent Biosciences (COGT)](https://longbridge.com/en/news/280026449.md)
- [Rafferty Asset Management LLC Purchases 57,139 Shares of Cogent Biosciences, Inc. $COGT](https://longbridge.com/en/news/277921641.md)